文献速递乳房整形与再造显微修复重建

阿哌沙班与依诺肝素用于整形外科VTE预防的随机对照试验

Venous Thromboembolism Chemoprophylaxis in Plastic Surgery: A Randomized Controlled Trial of Apixaban versus Enoxaparin.
PubMed 文献 · Plast Reconstr Surg · 2025-04-29

阿哌沙班组出血事件1例(3%),依诺肝素组1例(3%),校正后阿哌沙班vs依诺肝素的出血事件校正OR为1.0(99%CI 0.9-1.1);两组均无有症状VTE事件。结论认为阿哌沙班是自体乳房再造后安全的口服固定剂量VTE预防药。

要点

  • 阿哌沙班与依诺肝素出血事件各1例(3%),校正OR 1.0(99%CI 0.9-1.1)。
  • 两组均无有症状VTE事件报告。
  • 阿哌沙班为固定剂量口服,无需皮下注射。

核心结论

  • 阿哌沙班是自体乳房再造后安全的口服固定剂量VTE预防药,为重塑VTE预防范式提供新选择。

主要发现

  • VTE预防启动后出血事件:阿哌沙班组1例(3%)vs 依诺肝素组1例(3%)。
  • 校正人口学/临床特征的多变量logistic回归中,阿哌沙班vs依诺肝素的出血事件校正OR为1.0(99%CI 0.9-1.1)。
  • 两组均无有症状VTE事件报告。
  • 两组人口学与合并症相似。

关键数值与推荐

  • 阿哌沙班vs依诺肝素出血事件校正OR 1.0(99%CI 0.9-1.1)。
  • 证据等级:治疗性,II级。

临床怎么用

  • 在高危乳腺癌患者自体乳房再造后,可考虑使用阿哌沙班作为固定剂量口服VTE预防方案。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) remains an important safety issue in surgery. Although enoxaparin is the most common medication for VTE chemoprophylaxis in plastic surgery, several limitations have been discussed that may contribute to breakthrough VTE events. These include the following: (1) the need for weight-based dosing; (2) the need for factor Xa monitoring to ensure adequate therapeutic levels; and (3) the need for subcutaneous injection. Apixaban may represent a potential solution; however, experience with direct factor Xa inhibitors in the plastic surgery literature is limited. Thus, the authors present a first-of-its-kind randomized controlled trial of apixaban versus enoxaparin for VTE chemoprophylaxis among high-risk breast cancer patients undergoing autologous breast reconstruction. METHODS: This was a single-center, blinded, randomized controlled trial comparing enoxaparin versus apixaban VTE chemoprophylaxis among women undergoing microsurgical breast reconstruction with free abdominal flaps. RESULTS: Seventy-nine eligible patients were enrolled, of whom 40 (51%) were randomized to enoxaparin and 39 (49%) were randomized to apixaban. Treatment groups demonstrated similar demographics and comorbidities. Overall, of bleeding events that occurred after initiation of VTE chemoprophylaxis, 1 (3%) occurred in the apixaban arm and 1 (3%) occurred in the enoxaparin arm. On multivariable logistic regression adjusting for demographic/clinical characteristics, the adjusted odds of a bleeding event for apixaban versus enoxaparin was 1.0 (99% CI, 0.9 to 1.1). There were no symptomatic VTE events reported in either treatment arm. CONCLUSIONS: Apixaban is a safe fixed-dose, oral VTE chemoprophylaxis agent for use after autologous breast reconstruction. It presents a novel paradigm shift in VTE prevention after reconstructive surgery. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Momeni A, Yesantharao PS, Meyer S, et al. Venous Thromboembolism Chemoprophylaxis in Plastic Surgery: A Randomized Controlled Trial of Apixaban versus Enoxaparin. Plast Reconstr Surg. 2025. PMID: 40327806. doi:10.1097/PRS.0000000000012168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。